&NA;ARR 15896AR (ARR 15896, ARL 15896, ARL 15896AR, FPL 15896AR, FPL 15896) is a noncompetitive NMDA antagonist which is in development with Astra for intravenous administration in acute stroke. The compound is similar to remacemide, and appears to have completed phase I trials in Europe, and phase II trials are underway in the USA. ARR 15896AR may also have potential for the treatment of epilepsy. The drug was originally in development with Fisons, who sold their R&D activities to Astra.